GlobeNewsWire
09 Jan 2026, 13:30 UTC · 36w ago
Verdict
Headline takes no side. We score CGON +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 73% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
CG Oncology has moved the expected topline data readout for the Phase 3 PIVOT-006 trial to the first half of 2026, nearly one year ahead of schedule.
More positive than 92% of claims this week
The PIVOT-006 trial targets a U.S. patient population estimated at more than 50,000 individuals with intermediate-risk non-muscle invasive bladder cancer (IR NMIBC).
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 77% of claims this week
The expedited timeline for the PIVOT-006 trial was driven by the 'unprecedented' early completion of patient enrollment across over 90 sites.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 73% of ticker scores this week
The company announced that its Phase 3 clinical trial data is expected nearly one year ahead of schedule due to rapid enrollment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
5h ago
+85.4%
Price agrees with the score
$77.74 vs $41.93 close before publication (Jan 8) · not market-adjusted
CGON chart →